REPL

Replimune Group (REPL)

About Replimune Group (REPL)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Details

Daily high

$15.39

Daily low

$14.68

Price at open

$15.19

52 Week High

$15.70

52 Week Low

$1.50

Market cap

1.3B

Dividend yield

Volume

81,558

Avg. volume

8.2M

P/E ratio

-4.27

Replimune Group News